News | September 30, 2023
Advent International announces the completion of the acquision of Suven Pharma
New Board of Directors and management team at Suven Pharma also appointed
New Board of Directors and management team at Suven Pharma also appointed
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Subscribe To Our Newsletter & Stay Updated
